The authors concluded that RAAS inhibitors do not increase the risk of COVID-19 requiring admission to the hospital, including fatal cases and those admitted to intensive care units (ICUs), and should not be discontinued to prevent a severe case of COVID-19.

This case population study reports that the current use of RAAS inhibitors is not associated with an increased risk of COVID-19 requiring admission to the hospital (including fatal cases and those admitted to an ICU) compared with other antihypertensive drugs.

There were no substantial differences between angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, or among short-term and long-term users.

Furthermore, sex, age, and background cardiovascular risk did not significantly affect the results, although use of RAAS inhibitors was associated with a reduced risk of COVID-19 requiring admission to the hospital in patients with diabetes.

Overall, this study and other available evidence suggests that RAAS inhibitors are safe and should not be discontinued for fear of an increased risk of COVID-19.

Read More